= Additional active ingredients
Losartan potassium 50 mg, hydrocholorthiazide 12.5 mg.
PRESENTATION AND DOSSAGE
TABS: 30 x 50/12.5 mg
Treatment of hypertension, for patients in whom combination therapy is appropriate. To reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy.
Hypersensitivity to components, hypersensitivity to sulfonamide derived drugs, anuria, pregnancy, severe renal impairment, intravascular depletion.
Lactation: A decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. Safety and effectiveness of use in children have not been established. Changes in renal function, including renal failure, have been reported in susceptible individuals; these changes may be reversible upon discontinuation of therapy. A lower dose should be considered for patients with a history of hepatic impairment. In patients who are intravascularly volume-depleted, symptomatic hypotension may occur. These conditions should be corrected prior to administration of therapy, or a lower starting dose should be used. See literature.
For the most part, adverse experiences have been mild and transient in nature and have not required discontinuation of therapy: Abdominal pain, asthenia/fatigue, chest pain, edema/swelling, palpitation, tachycardia, diarrhea, dyspepsia, nausea, back pain, muscle cramps, dizziness, headache, insomnia, cough, nasal congestion, pharyngitis, upper respiratory infection. Anaphylactoid reactions, vasculitis, hepatitis, anemia, myalgia, migraine, cough, urticaria, pruritis, heart failure. See literature.
MANUFACTURER & DISTRIBUTER:
Manufacturer: Dexcel Pharma Technologies